‘Holy grail' diet pill burns fat without affecting appetite or muscle mass unlike weight loss jabs
The potential new drug treatment for people with type 2 diabetes and obesity, which is taken in tablet form, works in a completely different way to GLP-1 injections such as Ozempic and Wegovy.
These injections work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
These injections affect the hunger signals between the gut and the brain, but can often cause a loss of appetite, reduced muscle mass and gastrointestinal problems – leaving people feeling weaker or saggy.
However, the new drug works by triggering the metabolism in the muscles, activating them to burn more fat.
In animal studies, the treatment has shown good effects on both blood sugar control and body composition, but without the side effects associated with today's GLP-1-based drugs.
The study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University, revealed an initial clinical trial involving 48 healthy participants and 25 people with type 2 diabetes found humans can also tolerate the treatment.
"Our results point to a future where we can improve metabolic health without losing muscle mass. Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy," said one of the researchers behind the study, Tore Bengtsson, professor at the Department of Molecular Bioscience, Wenner-Gren Institute, Stockholm University.
The drug is based on a substance – a type of β2 (beta) agonist – which researchers have developed in a lab. Beta 2 agonist drugs are commonly used to treat asthma, but they can cause side-effects such as an increased heart rate or tremors.
Researchers say the molecule they created has a positive effect on the muscles without overstimulating the heart.
'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity. Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections," said Shane Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet, who is one of the researchers behind the study.
The next step for researchers is a clinical study planned by Atrogi AB, the company developing the treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
New genetic test could predict if you'll get condition suffered by 100million Americans decades before it develops
Genetic testing may predict your odds of becoming obese years - possibly even decades - before the condition strikes, researchers have revealed. A group of 600 researchers worldwide compiled genetic data from 5million people, the largest and most diverse dataset to date. They used that data to create a polygenic risk score, a person's genetic predisposition for a specific disease. In this case, it determined the odds of having a higher body mass index (BMI) in adulthood. The team found the score could be used to predict a person's risk of becoming obese as an adult - even for people as young as five years old. This could be instrumental for early intervention and preventing obesity - and its coexisting conditions. Ruth Loos, study co-author and professor at the University of Copenhagen's Novo Nordisk Foundation Center for Basic Metabolic Research, said: 'Childhood is the best time to intervene.' The score also was found to be up to twice as effective as those used in doctors offices based on factors like high blood pressure, heart disease, diet and exercise. Additionally, researchers found people with high polygenic risk scores were also more likely to regain weight after losing it through diet and exercise compared to those with lower scores. Loos added: 'Obesity is not only about genetics, so genetics alone can never accurately predict obesity. 'For the general obesity that we see all over the world, we need other factors such as lifestyle that need to be part of the predictions.' The findings come as more than 40 percent of Americans adults - 100million - are now obese, meaning they have a BMI of at least 30. Rates among young people in particular have surged the most, with quadruple the amount of teens being obese worldwide compared to the 1990s. The study, published Monday in the journal Nature Medicine, used genetic data from 5.1million people worldwide collected from 200 studies and 23andMe. The majority (71 percent) were of European ancestry, while 14 percent were of Hispanic ethnicity, eight percent were predominantly East Asian, five percent were African or African American and 1.5 percent were South Asian. Overall, the researchers found polygenic risk scores accounted for about 18 percent of a person with European ancestry's risk for having a high BMI as an adult compared to 8.5 percent on average for scores used by physicians. The remaining percentage is made up of lifestyle related factors like diet and exercise. However, this rate varied depending on ethnicity. For East Asian Americans, the score explained 16 percent of the risk for high BMI, though it was just 2.2 percent for people from rural Uganda and five percent for African ancestry overall. Because most participants were European, the team said further research is needed to look at other groups, particularly those of African descent. Based on the polygenic risk score calculated in the study, more than 80 percent of a person's risk for obesity can be explained by factors other than genetics, including where people live, foods they have access to and how much they exercise. Dr Roy Kim, a pediatric endocrinologist at Cleveland Clinic Children's who was not involved with the research, told NBC News: 'Behavioral things are really important. Their environment, their access to healthy food, exercise opportunities, even their knowledge about healthy foods all affect a person's obesity risk.' In children, BMI increased at a faster rate in those with a higher genetic predisposition than those with a lower risk, which was most evident at just two and a half years old. Additionally, individuals with higher polygenic risk scores lost more weight in the first year of lifestyle interventions like diet and exercise than a control group. However, people with high scores who lost at least three percent of their baseline weight in the first year had a higher risk of regaining it in the years that followed compared to a control group. Dr Joel Hirschhorn, study author and professor of pediatrics and genetics at Boston Children's Hospital, told The New York Times: 'There is definitely predictive value in genetics.' He added that with the new study 'we are now a lot closer to being able to use genetics in a potentially meaningful predictive way.'
Telegraph
5 hours ago
- Telegraph
Fat jab makers bet on NHS to be role model for the world
Britain is too fat. One in four people is classed as obese and, on average, they will live nine years less than if they were a healthy weight. They are three times more likely to develop colon cancer and five times more likely to develop type 2 diabetes. Such statistics are not just a crisis in national health, they are also an economic nightmare for the NHS. 'Obesity has doubled since the 1990s and costs our NHS £11bn a year, triple the budget for ambulance services,' Health Secretary Wes Streeting said last month. 'Unless we curb the rising tide of cost and demand, the NHS risks becoming unsustainable.' It is a threat that the Government is taking seriously, with a new ambition to tackle the problem once and for all. 'We now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity,' Streeting says. A crucial part of the plan is the wide rollout of weight-loss injections which, up until this point, have largely been reserved for those who can afford them. The Government instead wants fat jabs to be available 'based on need and not the ability to pay' and is testing new approaches to speed up the rollout of obesity medicines. Public health officials are not the only ones watching closely. At Danish giant Novo Nordisk, which makes obesity jab Wegovy and diabetes drug Ozempic, which can be used off-label for weight loss, executives are eager to know what ministers' next step will be. Sebnem Avsar Tuna, its UK chief, says that the Government's plans could prove a game-changer for Novo Nordisk, showing the benefits of these medicines to the world. 'I think there's a big opportunity for the UK to be a role model,' she says. 'We just need to speed up in terms of getting into the actions, so it's not just on paper ... This is what needs to be shown, at the population health scale, to the entire world: what could be the outcome in a real-world setting.' Test case for the world In other words, Britain could be the test case for the world. If Wegovy can dramatically improve Britain's health – and cut costs – then surely other countries will follow. The Government says it is exploring whether it could bring in a new payment model for weight-loss treatments, so that it would pay pharmaceutical companies based on how well their drugs made the nation healthier. For now, details over the Government's plans remain sparse. The fat jab plans are part of a wider obesity strategy, which also includes curbing calories in supermarkets and getting the country exercising. Ministers have yet to publish a comprehensive strategy. The pharmaceutical industry is not yet clear on which weight-loss drugs could be offered more broadly, nor how they will be rolled out to patients or whether weight limits guiding who can qualify for the jabs will be softened. So far only Eli Lilly's skinny jab Mounjaro is offered on the NHS through GPs. Novo's obesity jab is currently just available through specialist weight management clinics on the public health service, although can be bought privately. Still, both jabs have strict requirements over who is eligible. A person would need to have a BMI of over 40 – classing them as severely obese – as well as at least four of five specific health conditions, which include type 2 diabetes and sleep apnea, to qualify for a weight loss jab when seeking the treatment through a GP. There are concerns that current limits means the drugs are too restricted. 'We should be doing it for people who are becoming obese,' says one government adviser. 'That way, we can get them down to something that looks close to a normal range and then they can go back to work and start paying taxes.' Old habits die hard However, there are concerns that public health officials may resist a broad roll-out of the fat jabs after years where obesity was viewed as a behavioural issue, not something to be treated with medicine. 'The problem is this is very contrary to the status quo in this field, which is: we think you should stop eating, and then you won't be as fat,' the adviser says. There is a 'culture war within the health system between the old school public health doctors who say it's all about behavioural change, and the people who say, 'Hang on a minute, we haven't done so bad with statins, we should do the same with obesity''. 'Wes is probably more inclined to go for the latter view. The trouble is, Wes is not making the decisions. It's being made by a whole load of old-school doctors.' Drug bosses are anxious to see any signs of progress. 'We just need to speed up in terms of getting it done,' says Avsar Tuna. A speedy roll-out could provide not just a boost for Britain's health but also a shot in the arm for Novo Nordisk, which has been struggling in the US. It has faced weaker demand for Wegovy after a boom in cheap replica fat jabs. In May it blamed the copycat drugs – which were allowed by US regulators because of supply issues at Novo Nordisk – for forcing it to slash sales and profit forecasts. Lars Fruergaard Jørgensen was unexpectedly ousted as chief executive at the same time. The arms race in weight loss Regulators have since banned the cheap replicas. Still, it is facing a more existential threat in the form of rival Eli Lilly, amid growing uptake of the US company's Mounjaro weight-loss jab. In a recent head-to-head trial, Mounjaro beat Novo's Wegovy for weight-loss. Barclays analyst Emily Field says she has heard anecdotally that patients prefer Mounjaro too. 'When you look at the side effects in terms of patients that discontinue the drug because they're not feeling well, the two drugs look very similar,' she says. 'But when you actually talk to doctors, they disagree with that. They say that patients just feel better on the Lilly drug.' Novo Nordisk has been racing to develop new medicines to show it can compete, though investors are not entirely convinced. Its share price is down more than 50pc over the past year. Field says the company was 'really hampered' by the fact it was hit by shortages last year. Avsar Tuna says the company has enough capacity to meet demand. 'I can say that we don't have any supply challenges,' she says. If the NHS were to rapidly step up orders, she believes Novo Nordisk could deliver. 'I think it's a positive problem to look at,' Avsar Tuna says. 'If the NHS really comes back and says, tomorrow, I want X number of products from you to be able to give it all to patients, that would be a good dream to have.' Whether the call will come is another matter. Government advisers remain concerned that public health chiefs will try to stand in the way of a sweeping roll-out. 'If you ask me, they're in a bit of a muddle about these drugs,' says one insider. Still, Streeting is clearly convinced that they are the answer to Britain's weight problems. 'This Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay,' the Health Secretary said last month. 'There can be no doubt that these drugs will support our shift from sickness to prevention and be a game-changer for millions.'
The Independent
5 hours ago
- The Independent
New test twice as effective as previous methods for predicting obesity
Scientists have developed a new DNA -based tool capable of predicting a child's risk of developing obesity in adulthood. The test, which analyses DNA from a blood sample, is thought to be twice as effective as previous methods and can identify risk before the age of five, allowing for targeted preventative strategies. Published in Nature Medicine, the scientists' research involved a vast genetic dataset of over five million people and can also predict how obese adults will respond to weight loss programmes. The World Obesity Federation forecasts that over half the global population will be overweight or obese by 2035. Despite its advancements, the new tool has limitations, such as being more accurate for people of European ancestry compared to those of African ancestry.
